Hologic (HOLX) Research Coverage Started at Evercore ISI

Evercore ISI initiated coverage on shares of Hologic (NASDAQ:HOLX) in a research report released on Wednesday morning, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $50.00 target price on the medical equipment provider’s stock.

A number of other equities analysts also recently issued reports on HOLX. Needham & Company LLC reaffirmed a buy rating and set a $48.00 price objective (up from $46.00) on shares of Hologic in a report on Tuesday, December 5th. Royal Bank of Canada reaffirmed a hold rating and set a $42.00 price objective on shares of Hologic in a report on Friday, September 22nd. Cowen raised shares of Hologic to a buy rating and set a $52.00 price objective on the stock in a report on Wednesday, December 20th. Jefferies Group reaffirmed a buy rating and set a $44.00 price objective (down from $49.00) on shares of Hologic in a report on Tuesday, October 10th. Finally, Piper Jaffray Companies reaffirmed a buy rating and set a $48.00 price objective on shares of Hologic in a report on Thursday, November 9th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Hologic has a consensus rating of Buy and a consensus price target of $48.64.

Hologic (HOLX) opened at $43.98 on Wednesday. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.61 and a current ratio of 0.79. The stock has a market cap of $12,066.67, a price-to-earnings ratio of 21.67, a price-to-earnings-growth ratio of 2.10 and a beta of 0.95. Hologic has a fifty-two week low of $35.76 and a fifty-two week high of $46.80.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.49 by $0.01. The firm had revenue of $802.90 million for the quarter, compared to the consensus estimate of $792.54 million. Hologic had a net margin of 24.70% and a return on equity of 21.69%. The business’s revenue for the quarter was up 10.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.52 EPS. sell-side analysts anticipate that Hologic will post 2.13 earnings per share for the current fiscal year.

In other Hologic news, Director Lawrence M. Levy sold 7,138 shares of the company’s stock in a transaction dated Monday, October 9th. The shares were sold at an average price of $37.38, for a total transaction of $266,818.44. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Lawrence M. Levy sold 9,596 shares of the company’s stock in a transaction dated Tuesday, October 10th. The shares were sold at an average price of $36.81, for a total transaction of $353,228.76. The disclosure for this sale can be found here. Insiders sold a total of 28,833 shares of company stock worth $1,107,270 over the last three months. 0.79% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HOLX. Parnassus Investments CA purchased a new stake in Hologic during the third quarter valued at about $277,062,000. Capital World Investors purchased a new stake in Hologic during the second quarter valued at about $312,441,000. HealthCor Management L.P. purchased a new stake in Hologic during the second quarter valued at about $76,604,000. Vanguard Group Inc. lifted its holdings in Hologic by 4.2% during the second quarter. Vanguard Group Inc. now owns 29,547,138 shares of the medical equipment provider’s stock valued at $1,340,850,000 after purchasing an additional 1,200,825 shares during the last quarter. Finally, Koch Industries Inc. lifted its holdings in Hologic by 15,554.1% during the second quarter. Koch Industries Inc. now owns 1,149,481 shares of the medical equipment provider’s stock valued at $1,125,000 after purchasing an additional 1,142,138 shares during the last quarter. 97.67% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This report was reported by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://www.com-unik.info/2018/01/06/hologic-holx-research-coverage-started-at-evercore-isi.html.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Analyst Recommendations for Hologic (NASDAQ:HOLX)

What are top analysts saying about Hologic? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Hologic and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit